Category: ASX Release

Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services Clinical trial contract is in final…

Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in Acute Myeloid Leukemia (AML) patients with extramedullary disease The study led by Associate Professor Anoop Enjeti will underpin future Phase 2/3 trials in the USA…

20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership, developing, managing, and implementing Race’s preclinical and clinical research programs…

Race Oncology Limited (“Race”) is pleased to announce a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically translatable drug combinations that…

Race Oncology Limited (ASX: RAC) is pleased to announce that it has received binding commitments to raise $5.4m (before associated costs) in an oversubscribed equity placement to new and existing institutional and sophisticated investors (Placement), and the commencement of a…

Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation An update on the Company’s Three Pillar strategy and recent related highlights Updates to the…

In >40 clinical trials, Bisantrene has been shown to have low cardiotoxicity This study will assess the molecular mechanisms of Bisantrene heart safety usingcurrent molecular biology techniques Led by an established chemotherapeutic cardiology experienced team at the University of Newcastle…

Former Senior Vice President of Clinical Development at Syneos Health Dr Fuller brings over 30 years’ experience in oncology, international markets, listedbusinesses and is a highly experienced pharmaceutical physician Appointment follows an intensive two-month recruitment process to find a CMO…

Professor Jianjun Chen of the City of Hope Hospital appointed to Race’s Scientific Advisory Board Prof Chen is one of the foremost leaders in the m6A RNA methylation field and discovered Bisantrene’s FTO-inhibiting activity His expertise will be instrumental in…

Bisantrene shown by the University of Chicago to target the Fat Mass and Obesity associated protein (FTO) Bisantrene able to treat skin cancer in mice via inhibition of FTO at non-toxic concentrations Confirms earlier FTO-targeted Bisantrene results by the City…